Studies indicate that the lifetime risk of CRC in individuals with PMS2 mutations ranges between 10% and 20%, significantly lower than that of MLH1, MSH2, and MSH6 mutation carriers (27). This evidence concerns the gene MLH1 and colorectal carcinoma.